Nikolay Conev

6.4k total citations
41 papers, 351 citations indexed

About

Nikolay Conev is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nikolay Conev has authored 41 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nikolay Conev's work include MicroRNA in disease regulation (7 papers), Lung Cancer Research Studies (7 papers) and Circular RNAs in diseases (6 papers). Nikolay Conev is often cited by papers focused on MicroRNA in disease regulation (7 papers), Lung Cancer Research Studies (7 papers) and Circular RNAs in diseases (6 papers). Nikolay Conev collaborates with scholars based in Bulgaria, United States and Italy. Nikolay Conev's co-authors include Ivan Donev, Maria Radanova, Trifon Chervenkov, Assia Konsoulova, Constanta Timcheva, Mila Petrova, Mustafa Özgüroğlu, Niels Reinmuth, Galina Statsenko and Jonathan W. Goldman and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Nikolay Conev

37 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nikolay Conev Bulgaria 12 181 142 96 77 67 41 351
Massimiliano Grassi Italy 9 120 0.7× 81 0.6× 66 0.7× 34 0.4× 101 1.5× 23 290
Guangyu Bai China 13 177 1.0× 112 0.8× 75 0.8× 39 0.5× 136 2.0× 33 401
Qiuyan Xu China 10 65 0.4× 108 0.8× 62 0.6× 60 0.8× 66 1.0× 24 269
Yuenan Huang China 9 102 0.6× 159 1.1× 126 1.3× 24 0.3× 27 0.4× 13 289
Zusen Wang China 14 86 0.5× 207 1.5× 187 1.9× 81 1.1× 57 0.9× 37 440
Anne Macgregor-Das United States 7 73 0.4× 226 1.6× 166 1.7× 44 0.6× 42 0.6× 7 346
Xuan Pei China 8 142 0.8× 120 0.8× 81 0.8× 102 1.3× 40 0.6× 17 311
Anni Innamaa United Kingdom 5 209 1.2× 89 0.6× 79 0.8× 49 0.6× 31 0.5× 13 343
Sandhya Kalavacherla United States 7 79 0.4× 103 0.7× 46 0.5× 69 0.9× 79 1.2× 25 272
Youguo Chen China 12 116 0.6× 129 0.9× 96 1.0× 16 0.2× 38 0.6× 36 323

Countries citing papers authored by Nikolay Conev

Since Specialization
Citations

This map shows the geographic impact of Nikolay Conev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nikolay Conev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nikolay Conev more than expected).

Fields of papers citing papers by Nikolay Conev

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nikolay Conev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nikolay Conev. The network helps show where Nikolay Conev may publish in the future.

Co-authorship network of co-authors of Nikolay Conev

This figure shows the co-authorship network connecting the top 25 collaborators of Nikolay Conev. A scholar is included among the top collaborators of Nikolay Conev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nikolay Conev. Nikolay Conev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Conev, Nikolay, et al.. (2025). Quality of Life, Oncorehabilitation, and <i>Cordyceps sinensis</i> in Breast cancer. Scripta Scientifica Medica. 57(4). 48–54.
2.
Conev, Nikolay, et al.. (2025). Tracheal Chondrosarcoma: A Case Report and Discussion. Case Reports in Oncology. 18(1). 1262–1268.
3.
Radanova, Maria, et al.. (2023). KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer. International Journal of Molecular Sciences. 24(16). 12753–12753. 4 indexed citations
4.
Conev, Nikolay, et al.. (2023). Circulating Histones to Detect and Monitor the Progression of Cancer. International Journal of Molecular Sciences. 24(2). 942–942. 18 indexed citations
5.
6.
Conev, Nikolay, et al.. (2022). Impact of travel burden on clinical outcomes in lung cancer. Supportive Care in Cancer. 30(6). 5381–5387. 5 indexed citations
7.
Chen, Yuanbin, Luis Paz‐Ares, Niels Reinmuth, et al.. (2022). Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report. JTO Clinical and Research Reports. 3(6). 100330–100330. 27 indexed citations
8.
Radanova, Maria, et al.. (2021). New Circulating Circular RNAs with Diagnostic and Prognostic Potential in Advanced Colorectal Cancer. International Journal of Molecular Sciences. 22(24). 13283–13283. 17 indexed citations
9.
Paz‐Ares, Luis, Yuanbin Chen, Niels Reinmuth, et al.. (2021). LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. Annals of Oncology. 32. S1338–S1338. 8 indexed citations
10.
Conev, Nikolay, et al.. (2020). 1698P The presence of COVID-19 makes more cancer patients distressed and time perception may distinguish them. Annals of Oncology. 31. S1002–S1002. 1 indexed citations
11.
Conev, Nikolay, et al.. (2020). The role of carboxylesterase enzymes in capecitabine therapy. 7(1). 7–7. 1 indexed citations
12.
Goldman, Jonathan W., Marina Chiara Garassino, Yuanbin Chen, et al.. (2020). LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology. 31. S1212–S1213. 17 indexed citations
13.
Goldman, Jonathan W., Marina Chiara Garassino, Yuanbin Chen, et al.. (2020). 379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology. 31. S1388–S1389. 2 indexed citations
14.
Conev, Nikolay, et al.. (2020). Sarcopenia as a negative predictive marker for treatment with pembrolizumab as a second line in patients with metastatic non-small cell lung cancer.. Journal of Clinical Oncology. 38(15_suppl). e21541–e21541. 1 indexed citations
15.
Conev, Nikolay, et al.. (2019). Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease. Annals of Oncology. 30. iv81–iv82. 1 indexed citations
16.
Donev, Ivan, et al.. (2019). One-minute time interval estimation as a novel potent indicator of emotional concerns in cancer patients prior to starting chemotherapy. Current Psychology. 40(8). 3997–4003. 2 indexed citations
17.
Conev, Nikolay, et al.. (2018). One-minute time interval estimation as a novel ultrashort tool for distress screening. Supportive Care in Cancer. 27(6). 2031–2037. 5 indexed citations
18.
Nikolova, Silviya, et al.. (2018). Association Between Serum CK-18 Levels and the Degree of Liver Damage in Fructose-Induced Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 16(7). 350–357. 11 indexed citations
19.
Tonev, Ivan, et al.. (2015). Primary Adenoid Cystic Carcinoma of the Skin with Multiple Local Recurrences. Case Reports in Oncology. 8(2). 251–255. 5 indexed citations
20.
Sirakov, Stanimir, et al.. (2015). Embolization of bronchial arteries in cases of life-threatening bleeding. 21(1-2). 45–45.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Massimiliano Grassi Breakdown of academic impact, for papers by Guangyu Bai Breakdown of academic impact, for papers by Qiuyan Xu Breakdown of academic impact, for papers by Yuenan Huang Breakdown of academic impact, for papers by Zusen Wang Breakdown of academic impact, for papers by Anne Macgregor-Das Breakdown of academic impact, for papers by Xuan Pei Breakdown of academic impact, for papers by Anni Innamaa Breakdown of academic impact, for papers by Sandhya Kalavacherla Breakdown of academic impact, for papers by Youguo Chen
Rankless by CCL
2026